Janssen Biotech Inc. has reapplied for Medicare new technology add-on payments in 2023 for its recently-approved CAR-T therapy for multiple myeloma, Carvykti (ciltacabtagene autoleucel), despite indications that the Centers for Medicare and Medicaid Services may not believe the treatment meets the NTAP criteria for "newness."
Janssen Seeking Medicare Add-On Payments For CAR-T Carvykti, But CMS May Be Skeptical
J&J will need to convince the Centers for Medicare and Medicaid Services that its treatment is not substantially similar to existing CAR-T’s in order to qualify for supplemental Medicare reimbursement.
